These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 22482468)

  • 1. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).
    Stevenson W; Cheng SF; Dastjerdi MH; Ferrari G; Dana R
    Ocul Surf; 2012 Apr; 10(2):67-83. PubMed ID: 22482468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
    Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
    Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits.
    Kim EK; Kong SJ; Chung SK
    Cornea; 2014 Jan; 33(1):60-4. PubMed ID: 24240485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.
    Merz PR; Röckel N; Ballikaya S; Auffarth GU; Schmack I
    BMC Ophthalmol; 2018 Dec; 18(1):316. PubMed ID: 30537942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effectiveness and safety evaluation of anti-VEGF drugs on the treatment of corneal neovascularization].
    Wu X; Yang F
    Zhonghua Yan Ke Za Zhi; 2015 Oct; 51(10):730-3. PubMed ID: 26693766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
    Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C
    Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.
    Ahn YJ; Hwang HB; Chung SK
    Korean J Ophthalmol; 2014 Apr; 28(2):177-80. PubMed ID: 24688262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corneal neovascularization and biological therapy.
    Voiculescu OB; Voinea LM; Alexandrescu C
    J Med Life; 2015; 8(4):444-8. PubMed ID: 26664467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Topical inhibition of angiogenesis at the cornea. Safety and efficacy].
    Regenfuss B; Bock F; Bachmann B; König Y; Hos D; Parthasarathy A; Cursiefen C
    Ophthalmologe; 2009 May; 106(5):399-406. PubMed ID: 19396447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model.
    Liarakos VS; Papaconstantinou D; Vergados I; Douvali M; Theodossiadis PG
    Eur J Ophthalmol; 2014; 24(3):299-308. PubMed ID: 24242219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrastromal injection of bevacizumab in patients with corneal neovascularization.
    Vieira AC; Höfling-Lima AL; Gomes JÁ; Freitas Dd; Farah ME; Belfort R
    Arq Bras Oftalmol; 2012; 75(4):277-9. PubMed ID: 23258661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical ranibizumab as a treatment of corneal neovascularization.
    Ferrari G; Dastjerdi MH; Okanobo A; Cheng SF; Amparo F; Nallasamy N; Dana R
    Cornea; 2013 Jul; 32(7):992-7. PubMed ID: 23407316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.
    Bucher F; Parthasarathy A; Bergua A; Onderka J; Regenfuss B; Cursiefen C; Bock F
    Acta Ophthalmol; 2014 Mar; 92(2):143-8. PubMed ID: 22994268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corneal neovascularization: an anti-VEGF therapy review.
    Chang JH; Garg NK; Lunde E; Han KY; Jain S; Azar DT
    Surv Ophthalmol; 2012 Sep; 57(5):415-29. PubMed ID: 22898649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term topical bevacizumab in the treatment of stable corneal neovascularization.
    Cheng SF; Dastjerdi MH; Ferrari G; Okanobo A; Bower KS; Ryan DS; Amparo F; Stevenson W; Hamrah P; Nallasamy N; Dana R
    Am J Ophthalmol; 2012 Dec; 154(6):940-948.e1. PubMed ID: 22967868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab (avastin) for corneal neovascularization--corneal light shield soaked application.
    Mackenzie SE; Tucker WR; Poole TR
    Cornea; 2009 Feb; 28(2):246-7. PubMed ID: 19158579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.
    Chen WL; Chen YM; Chu HS; Lin CT; Chow LP; Chen CT; Hu FR
    PLoS One; 2014; 9(4):e94205. PubMed ID: 24714670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
    Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
    Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
    Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
    Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model.
    Türkcü FM; Cinar Y; Türkcü G; Sahin A; Cingü AK; Yüksel H; Sahin M; Yıldırım A; Caça I
    Cutan Ocul Toxicol; 2014 Jun; 33(2):138-44. PubMed ID: 23859535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.